TDMS Study 05135-06 Pathology Tables
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
Facility: Battelle Northwest
Chemical CAS #: 78-79-5
Lock Date: None
Cage Range: All
Reasons For Removal: All
Removal Date Range: All
Treatment Groups: Include All
a Number of animals examined microscopically at site and number of animals with lesion
Page 1
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 70 PPM 220 PPM 700 PPM 2200 PPM 7000 PPM
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY
Animals Initially In Study 40 40 40 40 40 40
Scheduled Sacrifice 10 10 10 10 10 10
Early Deaths
Moribund Sacrifice 1 1 1 1 1 5
Natural Death 1 1 1 2 3 4
Accidently Killed 1
Survivors
Terminal Sacrifice 27 28 28 27 26 21
Animals Examined Microscopically 40 40 40 40 40 40
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM
Gallbladder (39) (10) (10) (12) (37) (33)
Inflammation, Suppurative 1 (8%) 1 (3%)
Intestine Large, Cecum (40) (12) (11) (14) (37) (37)
Parasite 1 (7%)
Intestine Small, Duodenum (39) (12) (10) (12) (37) (36)
Serosa, Inflammation, Chronic 1 (3%)
Intestine Small, Jejunum (40) (11) (11) (13) (38) (36)
Parasite 1 (3%)
Intestine Small, Ileum (40) (11) (11) (13) (37) (36)
Parasite 1 (3%)
Liver (40) (40) (39) (40) (40) (38)
Angiectasis 2 (5%) 1 (3%) 2 (5%)
Basophilic Focus 3 (8%) 1 (3%) 2 (5%) 4 (10%) 5 (13%) 4 (11%)
Clear Cell Focus 2 (5%) 1 (3%)
Deformity 1 (3%)
Eosinophilic Focus 1 (3%) 6 (15%) 5 (13%) 3 (8%)
Hematopoietic Cell Proliferation 2 (5%) 1 (3%)
Hyperplasia, Focal 1 (3%)
Infarct 1 (3%)
Inflammation, Chronic 1 (3%)
Mixed Cell Focus 1 (3%) 1 (3%) 2 (5%) 3 (8%)
Necrosis 1 (3%) 1 (3%) 2 (5%)
Vacuolization Cytoplasmic 22 (55%) 25 (63%) 27 (69%) 20 (50%) 24 (60%) 14 (37%)
Bile Duct, Hyperplasia 1 (3%)
Mesentery (1) (2) (2) (4) (2)
Angiectasis 1 (50%)
Necrosis 1 (100%) 2 (100%) 2 (100%) 2 (50%) 2 (100%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 2
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 70 PPM 220 PPM 700 PPM 2200 PPM 7000 PPM
____________________________________________________________________________________________________________________________________
ALIMENTARY SYSTEM - CONT
Pancreas (40) (40) (39) (40) (40) (38)
Angiectasis 1 (3%)
Focal Cellular Change 2 (5%) 1 (3%) 5 (13%) 3 (8%) 6 (16%)
Inflammation, Chronic 2 (5%) 1 (3%) 1 (3%)
Duct, Cyst 1 (3%) 1 (3%)
Salivary Glands (40) (12) (11) (13) (40) (38)
Inflammation, Suppurative 2 (5%)
Stomach, Forestomach (40) (40) (39) (40) (40) (38)
Angiectasis 2 (5%)
Infiltration Cellular, Mast Cell 1 (3%)
Epithelium, Hyperplasia 1 (3%) 2 (5%) 16 (40%) 19 (48%) 15 (39%)
Stomach, Glandular (40) (40) (39) (40) (38) (37)
Hyperplasia 1 (3%) 3 (8%) 2 (5%) 4 (11%)
Inflammation, Suppurative 1 (3%) 1 (3%) 2 (5%)
Necrosis 2 (5%)
Pigmentation, Hemosiderin 1 (3%) 1 (3%)
Ulcer 1 (3%) 1 (3%)
Tooth (1) (2)
Deformity 1 (50%)
____________________________________________________________________________________________________________________________________
CARDIOVASCULAR SYSTEM
Heart (40) (12) (11) (13) (40) (38)
Pericardium, Hemorrhage 1 (3%)
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM
Adrenal Cortex (40) (12) (11) (13) (39) (38)
Hematopoietic Cell Proliferation 1 (3%)
Hemorrhage 1 (3%)
Hyperplasia 6 (15%) 8 (21%) 6 (16%)
Hyperplasia, Focal 1 (3%)
Hypertrophy, Focal 5 (13%) 6 (15%) 4 (11%)
Islets, Pancreatic (40) (40) (39) (40) (40) (38)
Angiectasis 1 (3%)
Hyperplasia 9 (23%) 9 (23%) 12 (31%) 12 (30%) 16 (40%) 13 (34%)
Pituitary Gland (38) (12) (10) (13) (37) (35)
Pars Distalis, Cyst 2 (5%) 1 (10%)
Pars Intermedia, Hyperplasia 1 (3%)
Thyroid Gland (40) (12) (11) (13) (39) (38)
Cyst 1 (3%) 1 (3%) 1 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 3
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 70 PPM 220 PPM 700 PPM 2200 PPM 7000 PPM
____________________________________________________________________________________________________________________________________
ENDOCRINE SYSTEM - CONT
Follicular Cell, Hyperplasia 1 (3%)
____________________________________________________________________________________________________________________________________
GENERAL BODY SYSTEM
None
____________________________________________________________________________________________________________________________________
GENITAL SYSTEM
Epididymis (40) (12) (11) (13) (40) (39)
Hyperplasia 1 (3%)
Inflammation 1 (8%) 1 (3%)
Preputial Gland (40) (13) (11) (16) (39) (37)
Angiectasis 1 (6%) 1 (3%)
Atrophy 1 (3%) 1 (3%)
Hemorrhage 1 (8%)
Inflammation, Chronic 1 (6%) 1 (3%)
Inflammation, Suppurative 1 (3%) 3 (23%) 1 (3%)
Necrosis 1 (8%)
Prostate (38) (12) (11) (13) (39) (37)
Hyperplasia 2 (5%)
Inflammation, Suppurative 2 (15%)
Seminal Vesicle (40) (12) (11) (13) (40) (38)
Inflammation, Suppurative 1 (8%)
Testes (40) (40) (39) (40) (40) (39)
Atrophy 1 (3%) 8 (21%)
Mineralization 1 (3%)
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM
Bone Marrow (40) (12) (11) (13) (40) (38)
Angiectasis 1 (3%)
Hyperplasia 1 (3%) 1 (8%) 2 (5%) 4 (11%)
Lymph Node (1) (1)
Iliac, Hyperplasia 1 (100%) 1 (100%)
Inguinal, Hyperplasia 1 (100%)
Lymph Node, Mesenteric (40) (13) (9) (13) (39) (37)
Hyperplasia 1 (8%) 1 (8%) 1 (3%)
Necrosis 1 (8%)
Lymph Node, Mediastinal (19) (10) (7) (9) (20) (22)
Hyperplasia 1 (5%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 4
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 70 PPM 220 PPM 700 PPM 2200 PPM 7000 PPM
____________________________________________________________________________________________________________________________________
HEMATOPOIETIC SYSTEM - CONT
Spleen (40) (15) (11) (13) (40) (38)
Accessory Spleen 1 (7%)
Hematopoietic Cell Proliferation 2 (5%) 1 (7%) 2 (5%) 4 (11%)
Infiltration Cellular, Histiocyte 1 (8%)
Necrosis 1 (7%)
Pigmentation, Melanin 1 (3%) 3 (20%) 1 (8%) 1 (3%)
Thymus (40) (12) (11) (13) (39) (36)
Atrophy 1 (8%) 1 (3%)
Necrosis 2 (17%) 1 (3%)
____________________________________________________________________________________________________________________________________
INTEGUMENTARY SYSTEM
Skin (40) (14) (11) (14) (40) (39)
Cyst Epithelial Inclusion 1 (3%)
Hemorrhage 1 (7%) 1 (3%)
Inflammation, Suppurative 2 (14%) 1 (3%)
Prepuce, Inflammation, Chronic 2 (5%) 1 (7%) 1 (7%) 2 (5%) 2 (5%)
Sebaceous Gland, Hyperplasia 1 (3%)
____________________________________________________________________________________________________________________________________
MUSCULOSKELETAL SYSTEM
Bone (40) (12) (12) (13) (40) (39)
Osteopetrosis 1 (8%)
Skeletal Muscle (40) (40) (39) (40) (40) (38)
Atrophy 4 (11%)
Inflammation 1 (3%) 1 (3%)
____________________________________________________________________________________________________________________________________
NERVOUS SYSTEM
Brain (40) (12) (11) (13) (40) (38)
Cyst Epithelial Inclusion 1 (9%)
Hemorrhage 2 (15%)
Mineralization 1 (3%) 2 (5%)
Necrosis 1 (8%)
Peripheral Nerve (40) (40) (39) (39) (38) (38)
Sciatic, Degeneration 1 (3%) 1 (3%) 5 (13%)
Spinal Cord (40) (40) (39) (40) (39) (38)
Degeneration 4 (10%) 20 (50%) 19 (49%) 28 (70%) 18 (46%) 23 (61%)
Meninges, Cyst Epithelial Inclusion 1 (3%) 1 (3%)
Meninges, Hemorrhage 1 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 5
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 70 PPM 220 PPM 700 PPM 2200 PPM 7000 PPM
____________________________________________________________________________________________________________________________________
RESPIRATORY SYSTEM
Larynx (40) (12) (11) (13) (38) (38)
Inflammation 1 (3%)
Lung (40) (40) (39) (40) (40) (38)
Congestion 3 (8%) 2 (5%)
Hemorrhage 3 (8%) 2 (5%) 2 (5%) 1 (3%) 2 (5%) 2 (5%)
Metaplasia, Osseous 1 (3%)
Thrombosis 1 (3%) 1 (3%)
Alveolar Epithelium, Hyperplasia 1 (3%) 1 (3%) 3 (8%) 5 (13%) 7 (18%)
Nose (40) (40) (39) (40) (40) (38)
Inflammation 2 (5%)
Turbinate, Inflammation 1 (3%) 1 (3%)
Turbinate, Inflammation, Suppurative 1 (3%)
Turbinate, Olfactory Epithelium, Degeneration 1 (3%) 2 (5%) 5 (13%) 12 (30%) 26 (65%) 38 (100%)
Turbinate, Olfactory Epithelium,
Inflammation, Chronic 1 (3%) 30 (79%)
____________________________________________________________________________________________________________________________________
SPECIAL SENSES SYSTEM
Eye (40) (12) (12) (13) (40) (40)
Inflammation, Chronic 1 (3%)
Harderian Gland (40) (40) (39) (40) (40) (38)
Hyperplasia 1 (3%) 3 (8%) 2 (5%) 3 (8%) 2 (5%)
____________________________________________________________________________________________________________________________________
URINARY SYSTEM
Kidney (40) (13) (11) (14) (40) (38)
Bilateral, Fibrosis 2 (5%) 1 (3%)
Bilateral, Fibrosis, Focal 1 (3%)
Bilateral, Hydronephrosis 2 (5%) 1 (8%) 1 (7%) 1 (3%) 1 (3%)
Bilateral, Metaplasia, Osseous 1 (3%) 1 (3%)
Bilateral, Nephropathy 1 (3%)
Bilateral, Cortex, Pelvis, Inflammation,
Suppurative 1 (7%)
Bilateral, Pelvis, Inflammation, Suppurative 1 (3%) 1 (8%) 1 (7%)
Bilateral, Renal Tubule, Hyperplasia 1 (3%) 2 (5%)
Urinary Bladder (40) (15) (11) (13) (40) (38)
Calculus Micro Observation Only 1 (3%) 1 (7%)
Dilatation 1 (3%) 2 (13%) 1 (8%)
Inflammation, Suppurative 2 (5%) 1 (3%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 6
NTP Experiment-Test: 05135-06 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03
Study Type: SIX MONTH EXPOS. ISOPRENE Date: 10/15/04
Route: RESPIRATORY EXPOSURE WHOLE BODY Time: 13:27:50
____________________________________________________________________________________________________________________________________
B6C3F1 MICE MALE CONTROL 70 PPM 220 PPM 700 PPM 2200 PPM 7000 PPM
____________________________________________________________________________________________________________________________________
URINARY SYSTEM - CONT
Transitional Epithelium, Hyperplasia 1 (3%) 1 (8%)
a Number of animals examined microscopically at site and number of animals with lesion
Page 7
------------------------------------------------------------
---------- END OF REPORT ----------
------------------------------------------------------------